ANUNCIO

Tipos de vacunas COVID-19 en boga: ¿podría haber algo extraño?

In the practice of medicine, one generally prefers time tested proven path while treating and trying to prevent diseases. An innovation is usually expected to pass the test of time. The three approved COVID-19 vacunas, two mRNA vaccines and one genetically engineered adenovirus vector DNA vaccine, are based on concepts and technologies that have never been used on human beings in the past (though few are approved for use in veterinary medicine). Inactivated vaccines stood the test of time for more than half a century and played key role in control and eradication of many infectious diseases. Were the disadvantages of good-old time-tested method of active immunity development through inactivated vaccines comprising of killed or attenuated germs heavy enough to discard altogether to opt for technologies that were never used on humans before? Apparently, the extraordinary situation presented by the pandemic seems to have superfast-tracked testing and use of the emergent, high potential vaccine and therapeutics development technologies which otherwise would have taken several years to see the light of the day. 

Los tres COVID-19 aprobados vacunas que actualmente se administra a las personas en el Reino Unido bajo un programa de inmunización masiva para combatir la pandemia según las prioridades establecidas por las autoridades son  

  1. BNT162b2 (fabricado por Pfizer / BioNTech): a vacuna de ARNm, lleva un mensaje para la expresión del antígeno proteico viral en las células humanas  
  2. ARNm-1273 (manufactured by Moderna): a mRNA Vacunas act in the same way as above 
  3. ChAdOx1 nCoV-2019 (por Oxford / AstraZeneca): básicamente, un Vacuna de ADN, utiliza adenovirus genéticamente modificados como vector para transportar el gen de proteína de punta del nuevo coronavirus que se expresa en las células humanas y que actúa como antígeno para el desarrollo de la inmunidad activa.  

Los tres mencionados anteriormente COVID-19 vacunas are expected to induce active immunity against novel coronavirus. The process of immunity development (both humoral and cellular) begins following exposure to antigens. In the case of mRNA vacunas, this happens after viral spike proteins are expressed in the human cells following injection of the vaccine containing viral messenger RNA. In the case of other, immunity development happens after expression of coronavirus DNA incorporated in the adenovirus. One may argue that these vacunas no son realmente vacunas en sentido estricto porque ellos mismos no son los antígenos y no pueden desencadenar la respuesta inmune per se hasta que se traduzcan en proteínas virales en células humanas. La vacuna, por definición, desencadena el proceso de desarrollo de la inmunidad activa, pero en el caso de estas tres vacunas tiene que esperar hasta que los genes virales se traduzcan en proteínas que, a su vez, podrían actuar como antígenos. Estas tres vacunas aprobadas se basan en tecnologías que nunca antes se usaron en humanos.   

In the last five decades or so, vacunas have played key role in dealing with prevention of several infectious diseases (except malaria). The time-tested gold standard was to use killed inactivated germs or germ parts as vaccine. It almost always worked. This is how several infectious diseases were controlled and some eradicated too in the past. 

If the current pandemic had struck humanity say a decade ago, we would still have used the good old time-tested vacunas made using killed germs but science has progressed much in the recent past. Advances in molecular biology of genes and its potential applications in therapeutics and vaccine development coupled with encouraging results on animal models meant saying goodbye to the existing method of inducing active immunity by exposing to weakened antigens. The idea of tricking human body to produce the viral proteins in the cells that could act as antigens for initiation of antibody formation against the self-manufactured viral proteins is sleek and smart and may be the beacon of future days to come. Just that neither mRNA nor genetically modified adenovirus has ever been used on human beings to trick the body to induce active immunity. Of course, there is first time for everything new. Yes, may be in the peacetime after studying impact for little longer period including on vulnerable population.  

True, these new techniques are answers to some of safety issues like reversion risks, unintentional spread or production errors etc associated with the olden types of vacunas. Plus, new methods are better targeted – specific antibody against specific viral antigen. But someone missed to take note of something that everyone knew that this pandemic is due to coronavirus, a virus that has a recent history of several epidemics in the past two decades, and a virus known to be notorious for rapid mutation because of lack of proofreading nuclease activity, thereby implying viral antigens are not going to remain static structurally for a long period of time. Apparently, this is what the situation looks like now.  

Yes indeed, clinical trials were successfully done for viral gene-based vacunas which proved safety and efficacy well within the permissible range. The same applies to the traditional whole virion inactivated COVID-19 vaccine as well whose initial efficacy of about 70% in trial in Brazil was brought down to 50.7% after some volunteers developed mild symptoms. But then whole virion inactivated vaccines are known to elicit mild reactions due to its very nature, possibly a trade-off for active immunity against wider range of antigens.    

The performance data of the three approved vacunas in the UK, especially pertaining to level of protection provided to the vulnerable people would tell the deeper story in future. For now, if the choice of a vaccine comprising of a wide range of antigens derived from killed inactivated virus may have been better for effectiveness over a longer period of time is in oblivion. May be, for vulnerable people viz. for those at higher risk due to advanced age or comorbidities, quick induction of passive immunity through anticuerpos neutralizantes puede haber sido una mejor opción y una vía de inmunidad activa para personas que por lo demás estaban sanas.

Aparentemente, la situación extraordinaria presentada por la pandemia parece tener pruebas superrápidas y el uso de tecnologías emergentes de desarrollo de vacunas y terapias de alto potencial que, de otra manera, hubieran tardado varios años en ver la luz del día. 

***

DOI: https://doi.org/10.29198/scieu/210101

*** 

Umesh Prasad
Umesh Prasad
Periodista científico | Editor fundador de la revista Scientific European

Suscríbase a nuestro boletín informativo

Para actualizarse con las últimas noticias, ofertas y anuncios especiales.

Artículos Populares

Efectos del donepezilo en las regiones del cerebro

Donepezilo es un inhibidor de la acetilcolinesterasa1. La acetilcolinesterasa descompone la ...

Imágenes de moléculas de resolución ultra alta a escala Ångström

Microscopía de resolución de nivel más alto (nivel de Angstrom) desarrollada que podría...

¿La dosis única de la vacuna COVID-19 brinda protección contra las variantes?

Un estudio reciente sugiere que una dosis única de Pfizer/BioNTech...
- Publicidad -
94,428VentiladoresMe gusta
47,668SeguidoresSeguir
1,772SeguidoresSeguir
30AbonadosSuscríbete